08/31/2026
NuvOx Therapeutics has received FDA Fast Track designation for NanO₂™ for the treatment of acute ischemic stroke.
The designation marks an important milestone as NuvOx advances NanO₂, its oxygen therapeutic designed to address tissue hypoxia, through clinical development.
With Fast Track, NuvOx gains opportunities for more frequent FDA interactions and expedited review pathways as it continues evaluating NanO₂ alongside standard stroke therapies.
Read more: https://www.nuvoxtherapeutics.com/post/nuvox-therapeutics-receives-fda-fast-track-designation-to-nano-for-the-treatment-of-acute-ischemic